Last reviewed · How we verify

NCT04520789

Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy

Status unknown NA Last updated 20 August 2020
What this trial tests

NA trial testing RPE cell collection and single cell heterogeneity study in Rhegmatogenous Retinal Detachment in 60 participants. Status unknown.

Timeline
1 September 2020
Primary endpoint
30 June 2022
31 December 2022

Quick facts

Lead sponsorShanghai 10th People's Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment60
Start date1 September 2020
Primary completion30 June 2022
Estimated completion31 December 2022

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai 10th People's Hospital

Who can join

Adults 18 to 60, any sex, with Rhegmatogenous Retinal Detachment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients; to prove the percentage of PVR-IC decides the risk of serious PVR occurring after surgery; to investigate the safety and efficacy of early local steroids drug intervention in patients with severe postoperative PVR.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rhegmatogenous Retinal Detachment

Currently open trials in the same condition.

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04520789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing